MSASPGI@EC2604A

Yashen Medicine's New Drug APG-3288 Receives FDA Clinical Approval

Ascletis to Deliver Presentation at J.P. Morgan Healthcare Conference

Yabio Medical Progresses with Phase III Study of Hycamtin Approved Globally by US and EU Authorities

Yabio Pharmaceuticals Presents Lisaftoclax Efficacy Data for Chronic Lymphocytic Leukemia

Yashen Pharmaceuticals' Olverabatinib Granted FDA and EMA Phase III Clinical Trial Approval

Ascentage Pharma to Present Bcl-2 Inhibitor Lisaftoclax Data at ASH Annual Meeting

Several Clinical Advances of Yabio's New Drugs Selected for ASH Annual Meeting

Yashen Pharmaceuticals Approved Innovative Drug Lisatoclax and Initiated Global Phase III Clinical Trial Registration

CICC Raises Target Price for Ascentage Pharma-B to HKD 105

Yashen Pharma-B Announces Mid-Year Report: Nilotinib Sales Grow 93%

Yashen Pharmaceuticals Group-B Reports Mid-Year Loss of 591 Million RMB

ASCENTAGE-B released FY2025 Q1 earnings on August 20 (BJT), actual revenue HKD 125.14 M, actual EPS HKD -0.9263

ASCENTAGE-B released FY2025 Q2 earnings on August 20 Pre-Market (BJT), actual revenue HKD 127.89 M, actual EPS HKD -0.9467

ASCENTAGE-B released FY2025 Semi-Annual Earnings on August 20 Pre-Market (BJT), actual revenue HKD 253.04 M, actual EPS HKD -1.8731

Yashen Pharmaceuticals' Lisatoclax Plus Azacitidine Phase III Clinical Trial for HR-MDS Approved by FDA and EMA

ASCENTAGE-B to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Ascentage Pharma's Innovative Drug Lisatoclax Receives Conditional Approval

Asia Biologics-B completes placement and issuance, raising HKD 1.4925 billion

Yashen Pharmaceuticals' Bcl-2 Inhibitor Approved for Market

Yabio Therapeutics Announces Rights Issue to Raise Capital

UNI PRINTSHOP

WING CHI HLDGS

CINESE INTL

WAN KEI GROUP

CHINA WACAN

JH EDUCATION

DIGITAL DOMAIN

LOTUS HORIZON

VICO INTL HLDGS

K W NELSON GP

06855

AAPG

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026. The management team is scheduled for a fireside chat at 9:30 am EST on February 12th. The event can be accessed via the Investor Relations section of Ascentage’s website.

Reuters

ASCENTAGE-B

VanEck Biotech ETF

Ascentage Pharma

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Ascentage Pharma has received IND clearance from the China CDE for its BTK-targeted protein degrader, APG-3288, following prior approval from the U.S. FDA. This marks a significant milestone in the clinical development of APG-3288, which aims to treat relapsed/refractory hematologic malignancies. The multicenter Phase I study will assess the drug's safety, tolerability, and efficacy. APG-3288 utilizes a novel mechanism to degrade BTK, potentially overcoming resistance seen with traditional BTK inhibitors. Ascentage Pharma continues to strengthen its pipeline in hematologic cancers with this innovative therapy.

StockTitan

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 | AAPG Stock News

Ascentage Pharma Group International has unveiled its 2026 global innovation strategy, focusing on expanding clinical development and product commercialization in hematologic malignancies and solid tumors. The plan includes advancing its innovative therapy pipeline, progressing multiple global Phase III trials, and developing APG-3288, a next-generation BTK degrader. The company aims to meet unmet clinical needs and enhance its global portfolio of products and clinical programs.

Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors

Ascentage Pharma Group International has received FDA IND clearance for its BTK degrader APG-3288, allowing it to initiate a global Phase I trial for patients with relapsed or refractory B-cell malignancies. This development enhances Ascentage's hematology pipeline and targets both wild-type and mutant BTK forms, potentially addressing treatment resistance. Despite a recent analyst rating of 'Buy' with a $50 price target, concerns about high debt and negative profitability have led to a low overall stock score, with some analysts rating it as 'Underperform.'

Tip Ranks

Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial

Ascentage Pharma has received IND clearance from the U.S. FDA for its next-generation BTK-targeted protein degrader, APG-3288. This marks a significant expansion of the company's innovative pipeline. The Phase I study will evaluate APG-3288 in patients with relapsed/refractory B-cell malignancies, aiming to address the urgent need for new treatments due to resistance to existing BTK inhibitors. APG-3288 utilizes Ascentage's PROTAC technology to induce degradation of BTK, potentially offering a novel therapeutic strategy in hematologic malignancies.

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 | AAPG Stock News

Ascentage Pharma Group International has enhanced its board structure by appointing Dr. Debra Yu to the nomination committee and naming Dr. David Sidransky as lead independent non-executive director. The company established a dedicated R&D committee for pipeline strategy oversight. A proposed equity grant to substantial shareholder Dr. Zhai Yifan will require independent shareholder approval, with part of her RSU vesting deferred until after the vote. The stock currently holds a Hold rating with a price target of HK$63.00.

Ascentage Pharma Enhances Board Structure, Sets Shareholder Vote on Equity Grant

Ascentage Pharma Group International has announced its board composition, led by Executive Director and Chairman Dr. Yang Dajun, featuring a mix of directors with expertise in science and industry. The company detailed its governance committees—Audit, Remuneration, Nomination, and R&D—emphasizing oversight and decision-making. The latest analyst rating for its stock (HK:6855) is a Hold with a price target of HK$63.00. Ascentage focuses on innovative drug R&D and is listed on the Hong Kong Stock Exchange under stock code 6855, with a market cap of HK$19.85B.

Ascentage Pharma Sets Out Board Line-Up and Key Committee Roles

Ascentage Pharma Group International has submitted an updated director list to the Hong Kong Stock Exchange. Dr. Yang Dajun is the Executive Director and Chairman, with Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as Non-executive Directors. The Board includes Independent Non-executive Directors such as Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu, and Marc E. Lippman, MD. The company has established Audit, Remuneration, Nomination, and Research and Development Committees.

Ascentage Pharma Group International Files Director List to HKEX

Ascentage Pharma Group International will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026, at 2:15 p.m. PT. This event highlights the company's participation in a major industry conference.

Ascentage Pharma to Present at J.P. Morgan Healthcare Conference

CICC analyst maintained a Buy rating on Ascentage Pharma Group International yesterday and set a price target of HK$89.00.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ascentage Pharma Group International with a HK$89.00 average price target.

Ascentage Pharma Group International (6855) Receives a Buy from CICC

Ascentage Pharma presented promising clinical data on Olverembatinib for second-line CML treatment at ASH 2025, showing a 76.7% complete cytogenetic response rate and a 60% major molecular response rate at 21 cycles. The data supports advancing Olverembatinib to earlier treatment lines. The findings update previous ASH 2024 results with longer follow-up data.

Ascentage Pharma Reports Promising Second-Line CML Results for Olverembatinib at ASH 2025

On August 6th, AI computing power and Apple's supply chain led the market rally. BYD Electronics surged over 10% in a single day due to iPhone 17 inventory expectations, Tencent Holdings hit a new high, XtalPi signed a HKD 47 billion cooperation agreement, and the innovative drug sector saw another wave of enthusiasm.

Apple

TENCENT-R

Tencent

Tencent Holdings Limited

TENCENT

BYD ELECTRONIC

Tencent HK SDR 10to1

XTALPI

BILIBILI-W

Bilibili

LEPU BIO-B

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

BIDU-SW

BIDU-SWR

Baidu

Hot Trades in Hong Kong Stocks (8.6)｜ AI + Apple Supply Chain Double Boost! BYD Electronics Soars 10%, Tencent Hits New High, Innovative Drugs Secure 47 Billion Mega Order!